MW33
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- MW33
- Accession Number
- DB16358
- Description
MW33 is a recombinant fully human antibody to SARS-CoV-2.2 This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Not Available
- External IDs
- MW33
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
The antibody MW33 targets the S protein epitope and is currently being investigated against COVID-19.1
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- DeFrancesco L: COVID-19 antibodies on trial. Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8. [PubMed:33087898]
- ClinicalTrials.gov: A Clinical Study to Evaluate MW33 Injection [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 16, 2020 13:46 / Updated on December 19, 2020 20:42